Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGFR2 CAR T-cell Therapy for Metastatic Cancer
NCT01218867Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Sep 2014
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-VEGFR2 chimeric antigen receptor CD8+ peripheral blood lymphocytes in metastatic cancer, melanoma and renal cell carcinoma (RCC) (11 cohorts), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With a Response to Therapy at 5 years. Started Nov 2010; status: terminated.
02
Drugs
anti-VEGFR2 chimeric antigen receptor CD8+ peripheral blood lymphocytes
03
Conditions
metastatic cancermelanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01218867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218867.